On November 9, 2026 PharmaLogic Holdings Corp. ("PharmaLogic" or the "Company"), the only independent contract development and manufacturing organization (CDMO) of scale dedicated exclusively to radiopharmaceuticals, reported a definitive agreement to acquire the CDMO business and Springfield, New Jersey manufacturing facility from Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH). The financial terms of the transaction were not disclosed.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Springfield facility is a state-of-the-art radiopharmaceutical manufacturing site with a proven track record in theranostic manufacturing, research and clinical development. Its highly skilled team will join Agilera, PharmaLogic’s therapeutic CDMO franchise, upon completion of the transaction. The transaction also includes a long-term supply agreement under which Agilera will manufacture lutetium Lu 177 dotatate for Lantheus.
The acquisition expands PharmaLogic’s capacity to manufacture radiopharmaceutical therapeutics in the U.S. Agilera brings more than 15 years of experience supporting the development and commercial launch of radioligand therapies (RLTs) and currently supplies an alpha therapy to more than 30 countries. With the Springfield facility, PharmaLogic becomes the first therapeutic CDMO to offer a transatlantic platform, giving partners an end-to-end solution for RLTs, from early clinical development through commercial launch and global supply.
"This acquisition strengthens Agilera’s unique capabilities in radioligand therapies and expands our capacity in the U.S.," said Etienne Montagut, President and Chief Executive Officer of PharmaLogic. "We are proud to welcome the talented Springfield team, who will help us scale our operations to meet growing demand from our partners and the patients they serve."
"We have a long-standing relationship with PharmaLogic, which has been an important manufacturing partner for our PET products," said Mary Anne Heino, Executive Chairperson and Chief Executive Officer of Lantheus. "With its proven radiopharmaceutical expertise and manufacturing capabilities, PharmaLogic is the right long-term owner for the CDMO business and Springfield facility, with the capabilities to build on this foundation while supporting reliable supply of our newly approved radiotherapeutic for patients and healthcare providers."
The transaction is subject to applicable regulatory review and the satisfaction of other customary closing conditions. The parties will continue to operate independently until the closing.
Advisors
Leerink Partners served as financial advisor to the Company, and Goodwin Procter LLP served as legal advisor.
Solomon Partners Securities LLC served as financial advisor to Lantheus, and Covington & Burling LLP served as legal advisor.
(Press release, Lantheus, NOV 9, 2026, View Source [SID1234674505])